BCRX Stock — BioCryst Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$8.68

Market cap

$2,218.0M

Cash

$352.6M

Enterprise value

$2,260.8M

Balance sheet

Cash	$352.6M
Debt	$395.4M
Net cash	-$42.8M
Enterprise value	$2,260.8M
Basic shares	255.3M shares
Fully diluted shares	319.4M shares
Fully diluted market cap	$2,772.0M
Cash per share	$1.38

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BCRX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	navenibart	Phase 3	Hereditary Angioedema (HAE)	Q3 2027
Jul 13 - Aug 24	navenibart	Phase 3	Hereditary Angioedema (HAE)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ORLADEYO

Approved · Active

Aliases berotralstat

Target Plasma kallikrein

Partnerships Torii Pharmaceutical Co., Ltd.: collaboration for ORLADEYO

Indications

HAE attack prevention (Approved)

Status note Marketed in the United States (97% of H1 2026 ORLADEYO revenue from U.S. customers). European ORLADEYO business sold. Primary source of the company's revenue.

RAPIVAB

Approved · Active Modality: injection

Aliases peramivir injection

Target Neuraminidase

Indications

Acute uncomplicated influenza (Approved)

Status note Marketed in the United States.

Navenibart

Stage not disclosed · Active

Target Plasma kallikrein

Partnerships Kaken Pharmaceutical Co., Ltd.: license agreement (Aug 2025) for the Navenibart Licensed Product in Japan. Neopharmed (Irish affiliate): license agreement (May 2026) granting exclusive rights to commercialize navenibart for HAE attack prevention in Europe

Indications

HAE attack prevention (Stage not disclosed)

Status note Acquired via Astria Therapeutics, Inc. (merger closed January 23, 2026). Filing's excerpts do not state stage, modality, or target for navenibart; 10-K fallback section was not included in the source file.

BCX17725

Stage not disclosed · Active

Target KLK5

Status note Named as a product candidate with ongoing R&D spend ($5.2M Q2 2026); no indication, stage, modality, or target disclosed in the excerpts; 10-K fallback section was not included in the source file.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	navenibart
Lead indication	Hereditary Angioedema (HAE)
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06842823	Phase 3	Active, not recruiting	Sponsor	BCRX	—	Hereditary Angioedema (HAE)	Q3 2027
NCT07204938	Phase 3	Enrolling by invitation	Sponsor	BCRX	—	Hereditary Angioedema (HAE)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Astria Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	4,009,240	no change	0.87%	2026-08-14
OrbiMed Advisors	1,852,000	+426,800	0.35%	2026-08-14
Sphera Biotech	422,051	-444,413	0.60%	2026-08-14
ADAR1 Capital Management	133,000	+28,000	0.06%	2026-08-14
Ikarian Capital	16,756	+16,756	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

BCRX — BioCryst Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders